DE69838785D1 - Pharmazeutische mittel zur behandlung von zerebralen amyloidosis - Google Patents
Pharmazeutische mittel zur behandlung von zerebralen amyloidosisInfo
- Publication number
- DE69838785D1 DE69838785D1 DE69838785T DE69838785T DE69838785D1 DE 69838785 D1 DE69838785 D1 DE 69838785D1 DE 69838785 T DE69838785 T DE 69838785T DE 69838785 T DE69838785 T DE 69838785T DE 69838785 D1 DE69838785 D1 DE 69838785D1
- Authority
- DE
- Germany
- Prior art keywords
- treatment
- pharmaceutical agents
- cerebral amyloidosis
- amyloidosis
- cerebral
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/02—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements
- C07D295/027—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring
- C07D295/03—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring with the ring nitrogen atoms directly attached to acyclic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C211/00—Compounds containing amino groups bound to a carbon skeleton
- C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
- C07C211/26—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring
- C07C211/28—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring having amino groups linked to the six-membered aromatic ring by unsaturated carbon chains
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
- C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C217/06—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted
- C07C217/08—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to an acyclic carbon atom
- C07C217/10—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C43/00—Ethers; Compounds having groups, groups or groups
- C07C43/02—Ethers
- C07C43/03—Ethers having all ether-oxygen atoms bound to acyclic carbon atoms
- C07C43/14—Unsaturated ethers
- C07C43/164—Unsaturated ethers containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C43/00—Ethers; Compounds having groups, groups or groups
- C07C43/02—Ethers
- C07C43/03—Ethers having all ether-oxygen atoms bound to acyclic carbon atoms
- C07C43/14—Unsaturated ethers
- C07C43/17—Unsaturated ethers containing halogen
- C07C43/174—Unsaturated ethers containing halogen containing six-membered aromatic rings
- C07C43/1745—Unsaturated ethers containing halogen containing six-membered aromatic rings having more than one ether bound
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
- C07D211/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
- C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- Hospice & Palliative Care (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Psychiatry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/858,343 US6130221A (en) | 1997-03-05 | 1997-05-19 | Pharmaceutical agents that impede the initiation and progression of primary and secondary DMS disruptions |
PCT/US1998/010218 WO1998052898A1 (en) | 1997-05-19 | 1998-05-19 | Pharmaceutical agents for the treatment of cerebral amyloidosis |
Publications (1)
Publication Number | Publication Date |
---|---|
DE69838785D1 true DE69838785D1 (de) | 2008-01-10 |
Family
ID=25328087
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69838785T Expired - Lifetime DE69838785D1 (de) | 1997-05-19 | 1998-05-19 | Pharmazeutische mittel zur behandlung von zerebralen amyloidosis |
Country Status (7)
Country | Link |
---|---|
US (2) | US6130221A (de) |
EP (2) | EP0983222B1 (de) |
JP (1) | JP2002502375A (de) |
AU (1) | AU743845B2 (de) |
CA (1) | CA2290818A1 (de) |
DE (1) | DE69838785D1 (de) |
WO (1) | WO1998052898A1 (de) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5525339A (en) * | 1986-08-27 | 1996-06-11 | Dms Pharmaceutical Inc. | Isolated components of dense microspheres derived from mammalian brain tissue and antibodies thereto |
GB9911802D0 (en) * | 1999-05-20 | 1999-07-21 | Merck Sharp & Dohme | Therapeutic combination |
CA2387857A1 (en) | 1999-10-27 | 2001-05-03 | Sunol Molecular Corporation | Tissue factor antagonists and methods of use thereof |
EP1829535A3 (de) * | 1999-10-27 | 2007-10-24 | Tanox, Inc. | Gewebefaktor-Antagonisten und Verfahren zu deren Verwendung |
US20030060487A1 (en) * | 2000-04-12 | 2003-03-27 | Bamdad R. Shoshana | Treatment of neurodegenerative disease |
US20020160988A1 (en) * | 2001-02-20 | 2002-10-31 | Israel Institute For Biological Research | Compounds co-inducing cholinergic up-regulation and inflammation down-regulation and uses thereof |
US7544681B2 (en) | 2001-09-27 | 2009-06-09 | Ramot At Tel Aviv University Ltd. | Conjugated psychotropic drugs and uses thereof |
NZ535275A (en) * | 2002-03-04 | 2007-03-30 | Nymox Corp | Spheron components useful in determining compounds capable of treating symptoms of alzheimer's disease, and treatments and animal models produced therefrom |
US7514407B2 (en) * | 2002-03-04 | 2009-04-07 | Nymox Corporation | Spheron component peptides and pharmaceutical compositions |
KR20090048462A (ko) | 2006-07-17 | 2009-05-13 | 라모트 앳 텔-아비브 유니버시티 리미티드 | 통증완화용 gaba 접합체 |
CA2782514A1 (en) | 2009-12-09 | 2011-06-16 | Biolinerx Ltd. | Methods of improving cognitive functions |
MX2012009821A (es) | 2010-02-24 | 2012-10-09 | Univ Ramot | Formas cristalinas de la sal de tri-mesilato de perfenazina-gaba y proceso para producirlas. |
WO2012038963A1 (en) * | 2010-09-22 | 2012-03-29 | Ramot At Tel-Aviv University Ltd. | An acid addition salt of a nortriptyline-gaba conjugate and a process of preparing same |
CN103896729A (zh) * | 2012-12-28 | 2014-07-02 | 北大方正集团有限公司 | 一种制备4-氯双苯氯甲烷的方法 |
MX2022002282A (es) | 2019-08-28 | 2022-03-25 | Unilever Ip Holdings B V | Compuestos novedosos para aclarar la piel. |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL93018C (de) * | 1957-10-22 | |||
US3060242A (en) * | 1958-10-01 | 1962-10-23 | Dow Chemical Co | Aralkyl ether |
US4540564A (en) * | 1982-05-18 | 1985-09-10 | University Of Florida | Brain-specific drug delivery |
ES514340A0 (es) * | 1982-06-17 | 1983-09-01 | Ferrer Int | "procedimiento de obtencion de nuevos derivados de piperazina". |
BG41728A1 (en) * | 1984-12-28 | 1987-08-14 | Ninov | Crystal form of 1- benzhydryl- 4- adyl- piperazine dihydrochloride and method for its preparation |
US4816416A (en) * | 1986-08-27 | 1989-03-28 | Paul Averback | Microspheric bodies for use in screening therapies for Azheimer's disease and related conditions |
US4919915A (en) * | 1987-03-03 | 1990-04-24 | Paul Averback | Method for detecting the ability to prevent red-to-green congophilic birefringence |
US5231170A (en) * | 1986-08-27 | 1993-07-27 | Paul Averback | Antibodies to dense microspheres |
US5280032A (en) * | 1989-02-14 | 1994-01-18 | Toyama Chemical Co., Ltd. | 1,2-ethanediol derivative and salt thereof, process for producing the same, and cerebral function-improving agent comprising the same |
-
1997
- 1997-05-19 US US08/858,343 patent/US6130221A/en not_active Expired - Lifetime
-
1998
- 1998-05-19 DE DE69838785T patent/DE69838785D1/de not_active Expired - Lifetime
- 1998-05-19 JP JP55052498A patent/JP2002502375A/ja not_active Ceased
- 1998-05-19 CA CA002290818A patent/CA2290818A1/en not_active Abandoned
- 1998-05-19 EP EP98923520A patent/EP0983222B1/de not_active Expired - Lifetime
- 1998-05-19 EP EP07021294A patent/EP1930308A1/de not_active Withdrawn
- 1998-05-19 AU AU75793/98A patent/AU743845B2/en not_active Ceased
- 1998-05-19 WO PCT/US1998/010218 patent/WO1998052898A1/en active IP Right Grant
-
2000
- 2000-10-06 US US09/680,327 patent/US6518314B1/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
AU7579398A (en) | 1998-12-11 |
CA2290818A1 (en) | 1998-11-26 |
AU743845B2 (en) | 2002-02-07 |
US6130221A (en) | 2000-10-10 |
US6518314B1 (en) | 2003-02-11 |
EP0983222A1 (de) | 2000-03-08 |
WO1998052898A9 (en) | 1999-04-01 |
WO1998052898A1 (en) | 1998-11-26 |
JP2002502375A (ja) | 2002-01-22 |
EP1930308A1 (de) | 2008-06-11 |
EP0983222B1 (de) | 2007-11-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69929996D1 (de) | Pharmazeutisches mittel zur behandlung von diabetes | |
ATE308997T1 (de) | Mittel zur behandlung von erkrankungen der speiseröhre | |
ATE447947T1 (de) | Pharmazeutische zubereitungen zur behandlung von insulinresitenz | |
DE69630947D1 (de) | Mittel zur schmerzbehandlung | |
DE60023128D1 (de) | Pyrazolecarboxamide zur behandlung von fettleibigkeit und anderen erkrankungen | |
ATE235481T1 (de) | Substituierte benzopyranderivate zur behandlung von entzündungen | |
DE69825447D1 (de) | Gerät zur dermatologischen behandlung | |
DE69723476D1 (de) | Mittel zur behandlung von haar | |
DE59500555D1 (de) | Mittel zur Wasserbehandlung | |
DE69903543D1 (de) | Formulierungen zur behandlung von magen-speiseröhren reflux | |
DE69806801D1 (de) | Galenische präparation zur prävention und behandlung von hepatokarzinomen | |
ATA76995A (de) | Stabiles präparat zur behandlung von blutgerinnungsstörungen | |
DE69838785D1 (de) | Pharmazeutische mittel zur behandlung von zerebralen amyloidosis | |
DE69620691T2 (de) | Therapeutisches Mittel zur Behandlung der Hypercholesterinämie | |
DE59812049D1 (de) | Pharmazeutische zusammensetzung zur behandlung von schlaganfall und schädel-hirn-trauma | |
DE69807466D1 (de) | Triptolid-derivate nützlich zur behandlung von autoimmunkrankheiten | |
DE69825319D1 (de) | Präparat zur vorbeugung und behandlung von entzündungen | |
DE69420229T2 (de) | Pharmazeutische Zusammensetzung zur Behandlung von AIDS | |
DE69905214D1 (de) | Mittel zur Behandlung der Osteoporose | |
DE69834937D1 (de) | Antibiotika zur behandlung von magengeschwuren | |
ATE314064T1 (de) | L-acetylcarnitin und l-propionylcarnitin zusammensetzung zur verhütung und behandlung von nierenstörungen und nierenenkrankheit | |
ATE235494T1 (de) | Imino-aza-anthracyclonderivate zur behandlung von amyloidosis | |
DE60043648D1 (de) | Medikamente zur behandlung von periodontalen erkrankungen | |
DE69720410D1 (de) | Therapeutisches Mittel zur Behandlung hartnäckiger Hundedermatitis | |
DE69806062T2 (de) | Kombinationstherapie zur behandlung von aids |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8332 | No legal effect for de |